secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090744
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range
-----------------------------------------------------------------------------

- Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.
- Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.
- Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).
- FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.
- Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/0000950170-24-090744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024090744/rxst-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer